Tammy Blankenship, MD
Public Health & General Preventive Medicine · Tallahassee, FLNPI 1285670216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Astellas Pharma US Inc at 31.7% of the total. Reporting peaked in 2021 at $445 and has fallen 91.5% since, to $38 in 2025.
Across 52 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$346
- Novo Nordisk$189
- GSK$185
- AstraZeneca$110
- Johnson & Johnson$64
- Novartis$54
- plus $145 from 6 others
What the payments were for
- Food & beverage$1,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 20 | $346 |
| Novo Nordisk | 6 | $189 |
| GSK | 9 | $185 |
| AstraZeneca | 1 | $110 |
| Johnson & Johnson | 4 | $64 |
| Novartis | 4 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Esperion Therapeutics, Inc. | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Strongbridge US Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$110
How this compares
$1,093 in reported general payments places this provider in the 85th percentile of 34 public health & general preventive medicine providers in Florida.
See all public health & general preventive medicine providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $73,377 |
| MounjaroTirzepatide | 33 | $59,713 |
| OzempicSemaglutide | 38 | $58,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $42,856 |
| MyrbetriqMirabegron | 32 | $38,352 |
| InvokanaCanagliflozin | 31 | $25,171 |
| FarxigaDapagliflozin Propanediol | 16 | $21,362 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $20,709 |
| XareltoRivaroxaban | 21 | $19,107 |
| JardianceEmpagliflozin | 12 | $18,568 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $18,430 |
| JanuviaSitagliptin Phosphate | 12 | $17,842 |
| EntrestoSacubitril/Valsartan | 12 | $15,365 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 248 | $14,403 |
| TrulicityDulaglutide | 14 | $13,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $73,37769 claims |
| Novo NordiskOzempic, Tresiba | $189 | $66,14749 claims |
| Johnson & JohnsonInvokana, Xarelto | $64 | $44,27852 claims |
| GSKTrelegy Ellipta | $185 | $42,85634 claims |
| Astellas Pharma US IncMyrbetriq | $346 | $38,35232 claims |
| AstraZenecaFarxiga, Symbicort | $110 | $32,31942 claims |
| NovartisEntresto | $54 | $15,36512 claims |
| AbbVieSynthroid | $15 | $1,55320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 34 public health & general preventive medicine providers in Florida.
Other public health & general preventive medicine in Tallahassee
- A Lynn DolsonTallahassee$124
- Charles LewisTallahassee$20
- Charles HennekensBoca Raton$223K
- Gregory GrayGainesville$7K
- Mary Ann CabreraStuart$3K
- Duellyn PandisTampa$3K
- Claudia Giovanelli PorrataWellington$682
- John CarrozzellaOrlando$513
- Robert HarmonJacksonville$447
- David JohnsonNew Port Richey$270
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.